Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF COMMERCIAL OFFICER | January 22, 2024 | January 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date January 22, 2024 · Filed January 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2034-01-21 | Direct | 66,586 |
Reported balance
After 2024-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-22 · Grant · Acquired 66,586 · Balance 66,586 F2: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 1,291 |
Reported balance
Holding disclosure · report date 2024-01-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,291 F1: Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F2: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2024 Filed Jan 24, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 66,586 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001777 · form4-01242024_060110.xml · derivative · entry 2 Pigot Timothy · CIK 0001967140 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,586 Underlying: Common Stock · 66,586 shares Expires 2034-01-21 F2 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.